Boston Scientific adds to its strong device pipeline

Article Excerpt

Boston Scientific continues to add to its portfolio of medical devices used in minimally invasive procedures. The latest purchase lets it move into a new area, and bodes well for the stock’s outlook. We still see Boston Scientific as an attractive buy. BOSTON SCIENTIFIC, $65.95, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (bostonscientific.com; Shares o/s: 1.5 billion; Market cap: $95.2 billion; No divds.) recently announced the acquisition of Axonics Inc. (symbol AXNX on Nasdaq), a medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction. The purchase price is $3.7 billion. In January 2023, Axonics received U.S. Food and Drug Administration (FDA) approval for its fourth generation Axonics R20 neurostimulator; it’s a rechargeable SNM device with a battery life of 20 or more years. Axionix’s portfolio also includes the Bulkamid Urethral Bulking System for female stress urinary incontinence. Boston Scientific’s outlook is positive. In the past few months, it has gained regulatory approvals…